BIB vs. NDAQ
BIB (ProShares Ultra Nasdaq Biotechnology) is Leveraged Equities fund tracking the NASDAQ Biotechnology Index (200%), while NDAQ (Nasdaq, Inc.) is a stock. Over the past 10 years, BIB returned 8.87%/yr vs 16.45%/yr for NDAQ. At a 0.41 correlation, their price movements are largely independent.
Performance
BIB vs. NDAQ - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BIB achieves a 23.85% return, which is significantly higher than NDAQ's -8.78% return. Over the past 10 years, BIB has underperformed NDAQ with an annualized return of 8.87%, while NDAQ has yielded a comparatively higher 16.45% annualized return.
BIB
- 1D
- -1.09%
- 1M
- 19.54%
- 6M
- 21.46%
- YTD
- 23.85%
- 1Y
- 95.70%
- 3Y*
- 24.68%
- 5Y*
- 2.09%
- 10Y*
- 8.87%
NDAQ
- 1D
- -1.35%
- 1M
- -1.09%
- 6M
- -10.40%
- YTD
- -8.78%
- 1Y
- -0.60%
- 3Y*
- 21.92%
- 5Y*
- 9.61%
- 10Y*
- 16.45%
BIB vs. NDAQ - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 23.85% | 59.21% | -9.84% | -1.06% | -28.85% | -6.02% | 39.79% | 46.71% | -24.93% | 40.49% |
NDAQ Nasdaq, Inc. | -8.78% | 27.19% | 34.85% | -3.66% | -11.19% | 60.13% | 25.99% | 33.88% | 8.21% | 16.76% |
Correlation
The correlation between BIB and NDAQ is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.19 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.33 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.42 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.39 |
Correlation (All Time) Calculated using the full available price history since Apr 8, 2010 | 0.41 |
Over the past year, the correlation between BIB and NDAQ has dropped to 0.19 - well below their long-term average of 0.41, suggesting their price drivers have been diverging.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIB vs. NDAQ — Risk / Return Rank
BIB
NDAQ
BIB vs. NDAQ - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares Ultra Nasdaq Biotechnology (BIB) and Nasdaq, Inc. (NDAQ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BIB | NDAQ | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.38 | ||
| Sortino ratioReturn per unit of downside risk | +2.78 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.02 | +0.32 |
| Calmar ratioReturn relative to maximum drawdown | 5.69 | -0.03 | +5.71 |
| Martin ratioReturn relative to average drawdown | 17.20 | -0.06 | +17.26 |
Loading charts...
Drawdowns
BIB vs. NDAQ - Drawdown Comparison
The maximum BIB drawdown since its inception was -67.24%, roughly equal to the maximum NDAQ drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for BIB and NDAQ.
Loading charts...
Drawdown Indicators
| BIB | NDAQ | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.24% | -68.48% | +1.24% |
Max Drawdown (1Y)Largest decline over 1 year | -16.92% | -23.39% | +6.47% |
Max Drawdown (3Y)Largest decline over 3 years | -45.30% | -23.39% | -21.91% |
Max Drawdown (5Y)Largest decline over 5 years | -65.86% | -32.84% | -33.02% |
Max Drawdown (10Y)Largest decline over 10 years | -66.20% | -38.31% | -27.89% |
Current DrawdownCurrent decline from peak | -10.05% | -12.25% | +2.20% |
Average DrawdownAverage peak-to-trough decline | -32.62% | -23.78% | -8.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.59% | 10.60% | -5.01% |
Volatility
BIB vs. NDAQ - Volatility Comparison
The current volatility for ProShares Ultra Nasdaq Biotechnology (BIB) is 11.65%, while Nasdaq, Inc. (NDAQ) has a volatility of 13.08%. This indicates that BIB experiences smaller price fluctuations and is considered to be less risky than NDAQ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BIB | NDAQ | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.65% | 13.08% | -1.43% |
Volatility (6M)Calculated over the trailing 6-month period | 31.64% | 23.69% | +7.95% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.93% | 27.23% | +13.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 43.78% | 24.52% | +19.26% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 46.34% | 24.53% | +21.81% |
Dividends
BIB vs. NDAQ - Dividend Comparison
BIB's dividend yield for the trailing twelve months is around 0.33%, less than NDAQ's 1.27% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIB ProShares Ultra Nasdaq Biotechnology | 0.33% | 0.77% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NDAQ Nasdaq, Inc. | 1.27% | 1.08% | 1.22% | 1.48% | 1.27% | 1.00% | 1.46% | 1.73% | 2.08% | 1.90% | 1.80% | 1.55% |
Frequently Asked Questions
BIB and NDAQ have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NDAQ has higher volatility (13.08%) compared to BIB (11.65%). In terms of maximum drawdown, BIB dropped -67.24% vs NDAQ's -68.48%.
BIB currently has the higher Sharpe Ratio (2.35 vs -0.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BIB and NDAQ
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer